Related Experiment Videos
Estrogens and postoperative thrombosis evaluated by the radioactive iodine method
Surgery, Gynecology & Obstetrics
|September 1, 1980
Summary
Preoperative estrogen use in women undergoing uterine prolapse surgery significantly increased the risk of developing fibrin deposits, a marker for potential blood clots. Discontinue estrogen therapy before surgery to mitigate this risk.
Area of Science:
- Gynecology
- Vascular Surgery
- Pharmacology
Background:
- Atrophic vaginal mucosa is common in women undergoing uterine prolapse surgery.
- Estrogen therapy is sometimes used to manage atrophic vaginal mucosa.
- The risk of postoperative venous thromboembolism (VTE) is a concern in gynecological surgery.
Purpose of the Study:
- To investigate the effect of preoperative estrogen administration on the incidence of fibrin deposition.
- To determine if estrogen therapy influences postoperative VTE risk in patients with uterine prolapse.
Main Methods:
- A study involving women undergoing surgery for uterine prolapse.
- Preoperative treatment with varying doses and durations of ethinyl estradiol.
- Postoperative assessment using the 125I-fibrinogen uptake test and phlebography to detect fibrin deposits.
Main Results:
- A significantly higher incidence of fibrin deposits was observed in patients receiving preoperative estrogens compared to the control group (p < 0.001).
- Fibrin deposits occurred in 6 out of 11 women on 50 mcg daily for 3 weeks and 4 out of 8 women on 200 mcg daily for 12 days.
- The control group showed fibrin deposits in 18 out of 157 patients.
Conclusions:
- Preoperative estrogen therapy is associated with an increased risk of fibrin deposition.
- Estrogen administration should be avoided before uterine prolapse surgery.
- Patients on estrogen-containing medications should discontinue therapy preoperatively to reduce potential VTE risks.